Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
This predetermined meta-analysis focused on cardiovascular factors and included all seven randomized controlled trials from the tirzepatide T2D clinical development program, known as SURPASS, with a minimum duration of 26 weeks
Data was collected mid-September from n=301 U.S
*Correspondence: Huatian Gan, [email protected] These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Liangpunsakul, S
Market Highlights By Product, the oral medications segment dominated the market with the largest market share of 36.21% in 2025
US$ 28.54
US$ 27.72
US$ 23.98
US$ 25.76
US$ 23.06
US$ 21.79
US$ 25.47
